A 2-year Randomized, 3-arm, Double-blind, Non-inferiority Study Comparing the Efficacy and Safety of Ofatumumab and Siponimod Versus Fingolimod in Pediatric Patients With Multiple Sclerosis Followed by an Open-label Extension
Latest Information Update: 22 Aug 2024
At a glance
- Drugs Ofatumumab (Primary) ; Siponimod (Primary) ; Fingolimod
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms NEOS
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 14 Jun 2024 Planned number of patients changed from 180 to 120.
- 20 Apr 2024 Planned End Date changed from 1 Jun 2029 to 23 Dec 2031.
- 20 Apr 2024 Planned primary completion date changed from 4 Aug 2026 to 2 Mar 2027.